OVPENS Platform
Pipleline
Developing Products
That Are Potent, Enabling,
Novel and Safe
That Are Potent, Enabling,
Novel and Safe
Open – collaborate with leading pharma, co-development with promising candidates
Vectors – include both viral (HSV) and non-viral (Exosome) vector development technologies as drug delivery mechanisms
-
Open VectorHarness the potential of viral and non-viral vector -
PotentDevelop novel vectors with outstanding potency -
EnablingAdvance efficacy of other therapy agents -
NovelPioneering the platform approach with novel modifications, applications and combinations -
SafeBio-derived vectors modified for optimized safety profile
Oncolytic Virus (rHSV)
Replication-competent oHSV Products to Become Anti-tumor Backbone Treatment
